0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Long-Term Danazol Therapy in Autoimmune Thrombocytopenia: Unmaintained Remission and Age-Dependent Response in Women

Yeon S. Ahn, MD; Rafael Rocha, MD; Ravindra Mylvaganam, PhD; Rolando Garcia, MD; Robert Duncan, PhD; and William J. Harrington, MD
[+] Article and Author Information

Grant Support: Supported in part by grant 1R01 DK 33813 from the National Institutes of Health, by a Merit Review Award (0215-01), and by the Mary Beth Weiss Research Fund, the Kenneth Chasen Fund, the Friends for Life Fund, and the Cissy and Marvin Friedman Fund.

Requests for Reprints: Yeon Soong Ahn, MD, University of Miami Hospitals and Clinics, Center for Blood Diseases (D-1), 1475 NW 12 Avenue, Miami, FL 33136.

Current Author Addresses: Drs. Ahn, Mylvaganam, Garcia, and Harrington: University of Miami Hospitals and Clinics, Center for Blood Diseases (D-1), 1475 NW 12 Avenue, Miami, FL 33136.

Dr. Rocha: Department of Medicine, Lincoln Medical/Mental Health Center, 234 East 149th Street, Bronx, NY 10451.

Dr. Duncan: Fox Cancer Research Building, University of Miami, Department of Oncology, Division of Biostatistics, P.O. Box 016960, Miami, FL 33101.


© 1989 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1989;111(9):723-729. doi:10.7326/0003-4819-111-9-723
Text Size: A A A

Study Objective: To assess the long-term benefit and side effects of danazol therapy, and to delineate factors influencing the responses in patients with autoimmune thrombocytopenia.

Design: Before and after trial.

Setting: Referral-based hematology clinics and the University of Miami teaching hospitals.

Patients: Data were collected on 96 patients (60 women and 36 men, 45 of whom had had splenectomies) receiving danazol therapy for autoimmune thrombocytopenia and analyzed.

Intervention: Danazol was added to the previous therapy or begun as an initial therapy. Glucocorticoids were tapered gradually.

Measurements and Main Results: The overall response rate to danazol was 61.4%. Among responders, the platelet counts (mean ± SD) before and after danazol treatment were 36 ± 24 x 109/L and 145 ± 77 x 109/L, respectively, and the time to response was 2.7 ± 3 months. Sex, age, and the status of the spleen (absent or present) influenced the responses to danazol: In women, but not in men, response rates improved with advancing age, especially in the nonsplenectomized women. This may be because estrogen levels are high in younger women and low in older women and men. Danazol, when given longer than a year, induced remissions lasting for years even after its discontinuation, but early relapses were frequent when danazol was administered for less than 6 months. Platelet-associated IgG returned to normal range during unmaintained remission.

Conclusion: Danazol is best suited for long-term medical management of autoimmune thrombocytopenia. It is well tolerated, and lasting, unmaintained remissions often occur after prolonged danazol administration. Age, sex, and the status of the spleen influence the responses. When danazol therapy is used, glucocorticoids can be substantially reduced in dosage or withdrawn. Danazol is a good alternative to splenectomy in elderly persons, especially in women.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)